Immunohistochemistry (IHC) Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Antibodies (Primary antibodies and Secondary antibodies), Reagents (Histological Stains, Blocking Sera and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents), Equipment (Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment), Kits (IHC Kits for Human tissue, IHC Kits for Animal tissue)), By Application (Diagnostic applications (Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, Other diseases), Research Applications (Drug development and Testing, Other research applications), Forensic applications), By End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Other end users) and Region Forecast 2020-2031

Immunohistochemistry (IHC) Market size was valued at US$ 3.0 billion in 2024 and is expected to reach US$ 5.4 billion by 2031, growing at a significant CAGR of 8.5% from 2025-2031. Since personalized medicine has shown to be quite successful in treating non-small-cell lung cancer patients, its use is anticipated to rise. By providing the most thorough and precise histological subtyping of tumors feasible, immunohistochemistry techniques enable this method of treatment decision-making (supported by predictive immunohistochemistry and the assessment of relevant biomarkers).

The market is growing due to the rise in product approvals and the introduction of technologically sophisticated IHC equipment for illness diagnostics. To improve their market position, businesses keep releasing innovative items that generate income.  The leading players are launching new products, merging with other companies, expanding regionally, and engaging in other strategic efforts in the field of IHC to address the growing demand for IHC assays in cancer diagnostics.

Additionally, the improved accessibility of immunohistochemical assays that identify mutant proteins (such as BRAF V600E and IDH1 R132H) offers a useful substitute or supplementary method to molecular testing. These methods are valuable novel tools in contemporary cancer care since they are highly reproducible, involve a manageable level of technical and interpretative complexity, and are accessible for comparatively little money. Furthermore, multiplex and mutation-specific immunohistochemistry tests are significant advances that have boosted value in targeted therapy and personalized medicine. The demand for IHC in disease diagnosis has increased significantly due to improvements in IHC methods.  

Key Developments:

• In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK anti-PD1 immunotherapy, JEMPERLI.
• In January 2021, This benchtop in vitro diagnostic system is fully automated and is used for In-situ Hybridization (ISH) and IHC applications.